Quality healthcare stocks like Clinuvel are in this basket. CUV has as good a ROE as any of these and much better growth - and much more shorting which I see as a big benefit for CUV when they buy back those millions of shares as this stock is so tightly held. The takeover offer has already come for Ramsay, easy to see one come for Clinuvel which has an excellent pipeline which is not priced in at all. Large and growing cash pile and profits with an FDA, EMA, TGA approved drug would add to any business immediately.Australian healthcare sector set to outperform as pandemic fades out – Citi09 Mar 2022 09:48
- * Australian healthcare sector will benefit from the end of the COVID-19 pandemic, Citi Research says
- * Brokerage adds companies like Cochlear Ltd , CSL Ltd , Integral Diagnostics , Ramsay Health Care and
ASX-listed shares of Resmed Inc will outperform in the coming year- * Remains "positively disposed" to biotech giant CSL, retains "buy" rating and price target of A$335
All IMO DYOR
- Forums
- ASX - By Stock
- CUV
- Ann: CLINUVEL Extends CEO Employment Agreement
Ann: CLINUVEL Extends CEO Employment Agreement, page-21
Featured News
Add CUV (ASX) to my watchlist
|
|||||
Last
$13.96 |
Change
-0.200(1.41%) |
Mkt cap ! $699.0M |
Open | High | Low | Value | Volume |
$14.20 | $14.24 | $13.88 | $631.9K | 44.90K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 416 | $13.96 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.04 | 192 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 416 | 13.960 |
1 | 1435 | 13.920 |
2 | 262 | 13.880 |
1 | 192 | 13.860 |
1 | 192 | 13.830 |
Price($) | Vol. | No. |
---|---|---|
14.040 | 192 | 1 |
14.060 | 192 | 1 |
14.070 | 200 | 1 |
14.090 | 192 | 1 |
14.100 | 600 | 1 |
Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
Featured News
CUV (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online